Prostate cancer

• Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Not authorised
  2024-512754-16-00 5
• DUAL Pending
  2023-505453-40-00 7
• A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix … Pending
  2023-509255-14-01 4 "Advanced prostate cancer"
• A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate can … Pending
  2024-515194-10-00 5 "Metastatic hormone-sensitive prostate cancer with high tumor"
• An open-label phase 2/3 study to analyse the feasibility and evaluate the safety of intravenous administration of 99mTc-PSMA-T4 in patients … Pending
  2024-519358-35-00 10 "Feasibility analysis and safety evaluation of [99mTc]Tc-PSMA"
• Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the tr … Pending
  2024-519658-35-00 9 "Primary localised prostate cancer"
• Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Exp … Pending
  2025-520482-52-03 9
• 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending
  2025-520861-29-00 5 "Prostate cancer at risk of developing metastatic lesions"
• Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending
  2025-520868-17-00 5 "Cancer on the prostatic bed"
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 "Metastatic Castrate Sensitive Prostate Cancer - mCSPC"
• First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting
  2025-521886-28-00 1 2026-02-19 "Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metas"
• A Clinical Trial to Assess a New Anti-Cancer Treatment (called DSB2455) Given On Its Own in Patients with Advanced Malignancies Recruiting
  2023-508805-26-00 1 2024-10-23 "patients with active brain metastases, where the primary tum"
• [18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer Recruiting
  2023-504026-19-01 5 2024-06-05 "Prostate Cancer"
• A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer Recruiting
  2023-504063-17-00 1 2024-03-08 "Advanced Prostate Cancer"
• A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting
  2022-502654-14-00 4 2023-09-11 "Endometrial cancer"
• A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting
  2025-523165-19-00 1 2026-02-10 "Advanced, metastatic or unresectable solid tumors"
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 4 2025-12-17 "Prostate Cancer"
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 "Metastatic castration-resistant prostate cancer (mCRPC)"
• REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermed … Recruiting
  2025-521170-33-00 4 2025-11-05 "Prostate Cancer"
• A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre … Recruiting
  2024-512421-92-00 7 2025-10-14 "Unresectable, Locally Advanced or Metastatic Cancer"
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 "Patients with localised prostate cancer and high-risk featur"
• 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregion … Recruiting
  2023-504912-13-00 4 2025-01-09 "Prostate Cancer"
• Artificial Intelligence driven personalisation of radiotherapy and concomitant androgen deprivation therapy for prostate cancer patients Recruiting
  2024-510707-11-00 4 2024-10-21
• Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation Recruiting
  2022-501892-14-00 5 2024-10-14

Showing 1–24 of 44 trials